Esperion Therapeutis.Inc. buy Cantor Fitzgerald
Start price
12.11.25
/
50%
€2.78
Target price
12.11.26
-
Performance (%)
19.34%
Price
30.12.25
€3.31
Summary
This prediction is currently active. The prediction currently has a performance of 19.34%. This prediction currently runs until 12.11.26. The prediction end date can be changed by Cantor_Fitzgerald at any time. Cantor_Fitzgerald has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Esperion Therapeutis.Inc. | -3.466% | -3.466% |
| iShares Core DAX® | 0.794% | 2.841% |
| iShares Nasdaq 100 | 0.016% | -0.939% |
| iShares Nikkei 225® | 0.309% | -0.648% |
| iShares S&P 500 | 0.181% | -0.442% |
Comments by Cantor_Fitzgerald for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Esperion Therapeutics (NASDAQ:ESPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Ratings data for ESPR provided by MarketBeat
Stopped prediction by Cantor_Fitzgerald for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
Start price
Target price
Perf. (%)
€2.41
17.12.24
17.12.24
€7.61
17.12.25
17.12.25
25.63%
18.12.25
18.12.25
